BACKGROUND: In a recent study of several antidepressant drugs in hospitalized, non-Hispanic White patients, Binder et al. reported association of markers located within the FKBP5 gene with treatment response after 2 and 5 weeks. Individuals homozygous for the TT-genotype at one of the markers (rs1360780) reported more depressive episodes and responded better to antidepressant treatment. There was no association between markers in FKBP5 and disease. The present study aimed at studying the associated FKBP5 markers in the ethnically diverse Sequenced Treatment Alternatives to Relieve Depression (STAR*D) sample of non-hospitalized patients treated with citalopram. METHODS: We used clinical data and DNA samples from 1809 outpatients with non-psychotic major depressive disorder (DSM-IV criteria), who received up to 14 weeks ofcitalopram. A subset of 1523 patients of White non-Hispanic or Black race was matched with 739 control subjects for a case-control analysis. The markers rs1360780 and rs4713916 were genotyped on the Illumina platform. TaqMan-assay was used for marker rs3800373. RESULTS: In the case-control analysis, marker rs1360780 was significantly associated with disease status in the White non-Hispanic sample after correction for multiple testing. A significant association was also found between rs4713916 and remission. Markers rs1360780 and rs4713916 were in strong linkage disequilibrium in the White non-Hispanic but not in the Black population. There was no significant difference in the number of previous episodes of depression between genotypes at any of the three markers. CONCLUSIONS: These results indicate that FKBP5 is an important target for further studies of depression and treatment response.
RCT Entities:
BACKGROUND: In a recent study of several antidepressant drugs in hospitalized, non-Hispanic White patients, Binder et al. reported association of markers located within the FKBP5 gene with treatment response after 2 and 5 weeks. Individuals homozygous for the TT-genotype at one of the markers (rs1360780) reported more depressive episodes and responded better to antidepressant treatment. There was no association between markers in FKBP5 and disease. The present study aimed at studying the associated FKBP5 markers in the ethnically diverse Sequenced Treatment Alternatives to Relieve Depression (STAR*D) sample of non-hospitalized patients treated with citalopram. METHODS: We used clinical data and DNA samples from 1809 outpatients with non-psychotic major depressive disorder (DSM-IV criteria), who received up to 14 weeks of citalopram. A subset of 1523 patients of White non-Hispanic or Black race was matched with 739 control subjects for a case-control analysis. The markers rs1360780 and rs4713916 were genotyped on the Illumina platform. TaqMan-assay was used for marker rs3800373. RESULTS: In the case-control analysis, marker rs1360780 was significantly associated with disease status in the White non-Hispanic sample after correction for multiple testing. A significant association was also found between rs4713916 and remission. Markers rs1360780 and rs4713916 were in strong linkage disequilibrium in the White non-Hispanic but not in the Black population. There was no significant difference in the number of previous episodes of depression between genotypes at any of the three markers. CONCLUSIONS: These results indicate that FKBP5 is an important target for further studies of depression and treatment response.
Authors: Silvia Paddock; Gonzalo Laje; Dennis Charney; A John Rush; Alexander F Wilson; Alexa J M Sorant; Robert Lipsky; Stephen R Wisniewski; Husseini Manji; Francis J McMahon Journal: Am J Psychiatry Date: 2007-08 Impact factor: 18.112
Authors: Francis J McMahon; Silvia Buervenich; Dennis Charney; Robert Lipsky; A John Rush; Alexander F Wilson; Alexa J M Sorant; George J Papanicolaou; Gonzalo Laje; Maurizio Fava; Madhukar H Trivedi; Stephen R Wisniewski; Husseini Manji Journal: Am J Hum Genet Date: 2006-03-20 Impact factor: 11.025
Authors: P W Lavori; A J Rush; S R Wisniewski; J Alpert; M Fava; D J Kupfer; A Nierenberg; F M Quitkin; H A Sackeim; M E Thase; M Trivedi Journal: Biol Psychiatry Date: 2001-11-15 Impact factor: 13.382
Authors: Steven D Hollon; Richard C Shelton; Stephen Wisniewski; Diane Warden; Melanie M Biggs; Edward S Friedman; Mustafa Husain; David J Kupfer; Andrew A Nierenberg; Timothy J Petersen; Kathy Shores-Wilson; A John Rush Journal: J Psychiatr Res Date: 2005-10-21 Impact factor: 4.791
Authors: Thomas G Schulze; Martin Alda; Mazda Adli; Nirmala Akula; Raffaella Ardau; Elise T Bui; Caterina Chillotti; Sven Cichon; Piotr Czerski; Maria Del Zompo; Sevilla D Detera-Wadleigh; Paul Grof; Oliver Gruber; Ryota Hashimoto; Joanna Hauser; Rebecca Hoban; Nakao Iwata; Layla Kassem; Tadafumi Kato; Sarah Kittel-Schneider; Sebastian Kliwicki; John R Kelsoe; Ichiro Kusumi; Gonzalo Laje; Susan G Leckband; Mirko Manchia; Glenda Macqueen; Takuya Masui; Norio Ozaki; Roy H Perlis; Andrea Pfennig; Paola Piccardi; Sara Richardson; Guy Rouleau; Andreas Reif; Janusz K Rybakowski; Johanna Sasse; Johannes Schumacher; Giovanni Severino; Jordan W Smoller; Alessio Squassina; Gustavo Turecki; L Trevor Young; Takeo Yoshikawa; Michael Bauer; Francis J McMahon Journal: Neuropsychobiology Date: 2010-05-08 Impact factor: 2.328
Authors: Erick T Tatro; Timothy B Nguyen; Chad A Bousman; Eliezer Masliah; Igor Grant; J Hampton Atkinson; Ian P Everall Journal: J Neurovirol Date: 2010-10 Impact factor: 2.643
Authors: Katarzyna A Ellsworth; Irene Moon; Bruce W Eckloff; Brooke L Fridley; Gregory D Jenkins; Anthony Batzler; Joanna M Biernacka; Ryan Abo; Abra Brisbin; Yuan Ji; Scott Hebbring; Eric D Wieben; David A Mrazek; Richard M Weinshilboum; Liewei Wang Journal: Pharmacogenet Genomics Date: 2013-03 Impact factor: 2.089
Authors: Sungho Maeng; Joshua G Hunsberger; Brandon Pearson; Peixiong Yuan; Yun Wang; Yanling Wei; Joseph McCammon; Robert J Schloesser; Rulun Zhou; Jing Du; Guang Chen; Bruce McEwen; John C Reed; Husseini K Manji Journal: Proc Natl Acad Sci U S A Date: 2008-06-18 Impact factor: 11.205